Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
0.8944
Oct 30 • 3:59 PM ET Dollar change-0.0518 Percentage change(-5.47%)
Aftermarket Close
0.8999
Aftermarket • 7:59 PM ET Dollar change+0.0055 Percentage change(0.61%)
Index
RUT
Market Cap
574.63M
Enterprise Value
523.66M
Income
-69.89M
Sales
204.56M
Book/sh
0.34
Cash/sh
0.47
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
258
IPO
Jul 31, 1996
P/E
-
Forward P/E
12.09
PEG
-
P/S
2.81
P/B
2.63
P/C
1.90
P/FCF
-
EV/EBITDA
-
EV/Sales
2.56
Quick Ratio
5.16
Current Ratio
6.92
Debt/Eq
1.15
LT Debt/Eq
1.05
Option/Short
Yes / Yes
EPS (ttm)
-0.10
EPS next Y
0.07
EPS next Q
-0.01
EPS this Y
65.38%
EPS next Y
264.44%
EPS next 5Y
-
EPS past 3/5Y
30.48% 14.78%
Sales past 3/5Y
575.71% 273.49%
EPS Y/Y TTM
21.06%
Sales Y/Y TTM
24.39%
EPS Q/Q
-1.22%
Sales Q/Q
17.22%
Insider Own
1.43%
Insider Trans
0.00%
Inst Own
73.21%
Inst Trans
-0.92%
ROA
-13.01%
ROE
-29.24%
ROIC
-15.58%
Gross Margin
96.45%
Oper. Margin
-18.36%
Profit Margin
-34.17%
SMA20
-22.34%
SMA50
-30.72%
SMA200
-37.25%
Trades
Shs Outstand
642.47M
Shs Float
633.28M
52W High
2.01 -55.50%
52W Low
0.84 6.48%
Volatility
11.23% 6.03%
ATR (14)
0.08
RSI (14)
22.16
Beta
0.57
Rel Volume
1.62
Avg Volume
11.59M
Volume
18,809,306
Perf Week
-20.14%
Perf Month
-26.08%
Perf Quarter
-30.12%
Perf Half Y
-43.39%
Perf YTD
-32.24%
Perf Year
-27.87%
Perf 3Y
-53.17%
Perf 5Y
-41.92%
Perf 10Y
-54.37%
Prev Close
0.95
Price
0.89
Change %
-5.47%
Consensus
Strong Buy
Avg. Price Target
$3.62
Implied Upside
+304.7%
Analysts12incl. previous ratings
Rating Distribution7 Buy · 4 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 10, 2025Resumed
GS logoGGoldman
Sell$1+11.8%
May 08, 2025Downgrade
BNS logoBScotiabank
Sector Outperform → Sector Perform$1.50+67.7%
Feb 27, 2025Downgrade
RILY logoRB. Riley Securities
Buy → Neutral$3.50 → $2+123.6%
Feb 26, 2025Downgrade
HH.C. Wainwright
Buy → Neutral
Nov 05, 2024Initiated
HH.C. Wainwright
Buy$8+794.5%
Oct 16, 2024Initiated
BNS logoBScotiabank
Sector Outperform
Sep 09, 2024Initiated
LLeerink Partners
Outperform$7+682.6%
Apr 30, 2024Downgrade
RRobert W. Baird
Outperform → Neutral$4.50+403.1%
Apr 29, 2024Initiated
TD logoTTD Cowen
Buy$10+1,018.1%
Mar 15, 2024Reiterated
NNeedham
Buy$4 → $5+459.0%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROBERTSON MICHELLEEVP, CHIEF FINANCIAL OFFICERFeb 18 '26Option Exercise0.0027,500027,500Feb 19 06:10 PM
ROBERTSON MICHELLEEVP, CHIEF FINANCIAL OFFICERFeb 18 '26Sale1.949,85519,11917,645Feb 19 06:10 PM
JAMES ZIEGLEROfficerDec 15 '25Proposed Sale1.3720,00027,400Dec 15 05:33 PM
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.
CEOMr. Harout Semerjian
EVPMs. Michelle J. Robertson
Executive VP of Research & Development and Chief Medical OfficerDr. Joseph Emile Eid M.D.
Executive VP & Chief Commercial OfficerMr. Ahmed ElNawawi
Senior VP & Chief Technical OfficerMr. Shanthakumar Tyavanagimatt